Belite Bio, Inc. ADR (BLTE) Price & Analysis

Compare

47 Followers

BLTE Stock Chart & Stats

$154.02

-$1.45(-2.47%)

At close: Jan 08 4:00 PM EST

$154.02

-$1.45(-2.47%)

Day’s Range― - ―

52-Week Range$49.00 - $125.24

Previous CloseN/A

Volume15.47K

Average Volume (3M)64.23K

Market Cap

$3.62B

Enterprise Value$1.73B

Total Cash (Recent Filing)$0.00

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.94

Next Earnings

Mar 27, 2026

EPS Estimate

-0.53

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.65

Shares Outstanding32,833,400

10 Day Avg. Volume75,810

30 Day Avg. Volume64,229

Financial Highlights & Ratios

PEG Ratio63.44

Price to Book (P/B)13.21

Price to Sales (P/S)0.00

P/FCF Ratio-65.58

Enterprise Value/Market Cap0.48

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-35.30

Forecast

1Y Price Target

$167.50

Price Target Upside8.75% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe Phase 3 DRAGON trial of tinlarebant in adolescent Stargardt disease met the primary efficacy endpoint and demonstrated a significant reduction in the growth rate of retinal lesions compared with placebo.

Financial PositionThe company has a strong cash position, which should provide funding through the likely commercial launch of tinlarebant.

Regulatory ApprovalsTinlarebant has been granted Breakthrough Therapy, Fast Track, Rare Pediatric Disease, and Orphan Drug designations in the U.S., which should warrant accelerated approval in all territories.

Bears Say

Belite Bio, Inc. ADR News

Belite Bio price target raised to $200 from $140 at Maxim

Maxim raised the firm’s price target on Belite Bio (BLTE) to $200 from $140 and keeps a Buy...

1d ago

BLTE

Belite Bio 2.273M share Spot Secondary priced at $154.00

The deal range was $150.00-$154.00. Morgan Stanley, Leerink, BofA and Cantor Fitzgerald acted as joint book running managers...

2d ago

BLTE

Mizuho upgrades Belite to Buy on ‘impressive’ Stargardt data

Mizuho analyst Graig Suvannavejh upgraded Belite Bio (BLTE) to Outperform from Neutral with a price target of $194,...

2d ago

BLTE

Belite Bio upgraded to Outperform from Neutral at Mizuho

Mizuho analyst Graig Suvannavejh upgraded Belite Bio (BLTE) to Outperform from Neutral with a $194 price target Published...

2d ago

BLTE

Belite Bio TBA Spot Secondary; price range $150.00-$154.00

Morgan Stanley, Leerink, BofA and Cantor Fitzgerald are acting as joint book running managers for the offering. Published...

2d ago

BLTE

Belite Bio announces American Depositary shares offering, no amount given

Belite Bio (BLTE) announced that it has commenced an underwritten public offering of American Depositary shares, or ADSs,...

2d ago

BLTE

Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!

Traders will find all of Monday’s top stock market happenings in our daily roundup. ...

2d ago

Belite Bio price target raised to $185 from $98 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Belite Bio (BLTE) to $185 from $98 and keeps a...

3d ago

BLTE

Belite Bio Stock (BLTE) Jumps on Positive Phase 3 STGD1 Trial Data

Belite Bio stock was up on Monday after the company reported positive clinical trial data. ...

3d ago

BLTE

Belite Bio says tinlarebant met primary efficacy endpoint in Phase 3 trial

Belite Bio (BLTE) announced topline results from the global Phase 3 “DRAGON” trial of Tinlarebant, marking the first...

3d ago

BLTE

Belite Bio falls -9.3%

Belite Bio (BLTE) is down -9.3%, or -$12.65 to $123.35. Published first on TheFly – the ultimate source...

9d ago

BLTE

Belite Bio rises 16.3%

Belite Bio (BLTE) is up 16.3%, or $19.69 to $140.25. Published first on TheFly – the ultimate source...

10d ago

BLTE

Belite Bio Prices $350 Million ADS Offering to Boost Drug Development

Belite Bio, Inc. ADR ( ($BLTE) ) just unveiled an announcement. On December 1, 2025, Belite Bio announced...

1d ago

BLTE

Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs

The latest announcement is out from Belite Bio, Inc. ADR ( ($BLTE) ). Belite Bio, Inc. released its...

2d ago

BLTE

BLTE FAQ

What was Belite Bio, Inc. ADR’s price range in the past 12 months?

Belite Bio, Inc. ADR lowest stock price was $49.00 and its highest was $125.24 in the past 12 months.

What is Belite Bio, Inc. ADR’s market cap?

Belite Bio, Inc. ADR’s market cap is $3.62B.

When is Belite Bio, Inc. ADR’s upcoming earnings report date?

Belite Bio, Inc. ADR’s upcoming earnings report date is Mar 27, 2026 which is in 113 days.

How were Belite Bio, Inc. ADR’s earnings last quarter?

Belite Bio, Inc. ADR released its earnings results on Nov 10, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.488 by -$0.162.

Is Belite Bio, Inc. ADR overvalued?

According to Wall Street analysts Belite Bio, Inc. ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Belite Bio, Inc. ADR pay dividends?

Belite Bio, Inc. ADR does not currently pay dividends.

What is Belite Bio, Inc. ADR’s EPS estimate?

Belite Bio, Inc. ADR’s EPS estimate is -0.53.

How many shares outstanding does Belite Bio, Inc. ADR have?

Belite Bio, Inc. ADR has 32,833,400 shares outstanding.

What happened to Belite Bio, Inc. ADR’s price movement after its last earnings report?

Belite Bio, Inc. ADR reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.488. Following the earnings report the stock price went up 3.666%.

Which hedge fund is a major shareholder of Belite Bio, Inc. ADR?

Currently, no hedge funds are holding shares in BLTE

Belite Bio, Inc. ADR Stock Smart Score

Outperform

Fundamentals

Return on Equity

-32.30%

Trailing 12-Months

Asset Growth

32.07%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Belite Bio, Inc. ADR

Belite Bio, Inc. ADR (BLTE) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics to address significant unmet medical needs in the fields of ophthalmology and metabolic diseases. The company is engaged in developing innovative treatments aimed at improving patient outcomes, particularly in the areas of retinal degenerative diseases such as Stargardt disease and dry age-related macular degeneration.

Belite Bio, Inc. ADR (BLTE) Earnings & Revenues

Historic Earnings Reports

BLTE Company Deck

BLTE Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects significant regulatory progress and strong financial positioning through successful funding. However, these positives are counterbalanced by increased losses and rising expenses, primarily due to share-based compensation and trial costs.View all BLTE earnings summaries

BLTE Stock 12 Month Forecast

Average Price Target

$167.50

▲(8.75% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"47":"$47","124":"$124","201":"$201","85.5":"$85.5","162.5":"$162.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":167.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$167.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$85.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[47,85.5,124,162.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.02,157.55692307692308,161.09384615384616,164.63076923076923,168.1676923076923,171.70461538461538,175.24153846153848,178.77846153846156,182.31538461538463,185.8523076923077,189.38923076923078,192.92615384615385,196.46307692307693,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.02,155.05692307692308,156.09384615384616,157.13076923076923,158.1676923076923,159.20461538461538,160.24153846153845,161.27846153846156,162.31538461538463,163.3523076923077,164.38923076923078,165.42615384615385,166.46307692307693,{"y":167.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,154.02,148.71076923076924,143.40153846153848,138.0923076923077,132.78307692307692,127.47384615384615,122.16461538461539,116.85538461538462,111.54615384615386,106.23692307692308,100.92769230769231,95.61846153846153,90.30923076923077,{"y":85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":48.68,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.04,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":154.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >